EUR 0.3
(7.19%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -16.23 Million EUR | 10.29% |
2022 | -18.1 Million EUR | -253.41% |
2021 | -15.96 Million EUR | 183.55% |
2020 | -14.12 Million EUR | 22.97% |
2019 | -18.33 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 Q1 | -4172.00 EUR | 21.87% |
2023 FY | - EUR | 10.29% |
2023 Q2 | -4172.00 EUR | 0.0% |
2022 FY | - EUR | -253.41% |
2022 Q4 | -5339.50 EUR | 0.0% |
2021 FY | - EUR | 183.55% |
2020 FY | - EUR | 22.97% |
2019 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
European Medical Solutions | 59 Thousand EUR | 27622.034% |
FERMENTALG | -10.51 Million EUR | -54.5% |
PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 29.184% |